Quantcast

Latest PARP inhibitor Stories

2010-03-26 13:29:33

The presence of the protein poly (ADP-ribose) polymerase (PARP) in tumors can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona tomorrow (Saturday 27 March). Professor Gunter von Minckwitz, from the German Breast Group Forschungs GmBH, Neu-Isenburg, says that, contrary to current belief that PARP is associated with a limited number of tumors, he and his team found for the first time that PARP expression...

2010-02-24 07:00:00

WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, Sanofi-Aventis's BSI-201 will garner sales of $1.7 billion in the triple negative breast cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Owing to the improvement in overall survival rates it has demonstrated in clinical trials and the need for novel targeted...

2010-02-22 13:18:34

Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports. Susan Bates and Christina Annunziata looked at several recent papers on this form of treatment, which takes advantage of the synthetic lethality of BRCA (breast cancer susceptibility genes) and poly-ADP ribose polymerase (PARP) proteins to attack cancerous cells whilst sparing healthy...

2010-01-25 15:15:20

Breast cancer patients who have triple negative breast cancer, an aggressive form of the disease, that has spread to other parts of the body, are being asked to participate in a clinical study of a promising new treatment called PARP inhibitors. Researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine will conduct the study at both the Baylor Clinic and the Harris County Hospital District's Ben Taub General Hospital. "This is a very important study," said Dr....

2009-12-08 12:02:00

NEW YORK, Dec. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Poly(ADP-ribose) polymerase (PARP) Research Products http://www.reportlinker.com/p0167261/PolyADP-ribose-polymerase-PARP-Research-Products.html This PARP Research Products market report explores are a superfamily of 18 proteins, of which PARP-1 is the best characterized. They are enzymes that are activated by DNA breaks to facilitate DNA repair. Currently, there is...

2009-11-09 07:00:00

WALTHAM, Mass., Nov. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment. Continued uptake of Herceptin and Tykerb/Tyverb and the expected launches of three new...

2009-11-05 12:58:37

Selective eradication of malignant cells The ultimate goal in cancer research, a treatment that kills cancer cells whilst leaving healthy cells untouched, is brought nearer by the success of a new therapeutic approach. The potential therapy, published in BioMed Central's open access journal Breast Cancer Research, targets proliferation of cancer, but not normal, cells. An international research team led by Professor Cohen-Armon of Tel-Aviv University found that potent phenanthridine derived...

2009-08-09 09:31:03

The Stowers Institute's Conaway Lab has uncovered a previously unknown function of a gene product called Amplified in Liver Cancer 1 (Alc1), which may play a role in the onset of cancer. The work was published yesterday by the Proceedings of the National Academy of Science Early Edition."We've been able to demonstrate that the protein encoded by the Alc1 gene is, in fact, a chromatin remodeling enzyme," explained Aaron Gottschalk, lead author on the paper and a University of Kansas Medical...

2008-10-28 09:00:40

BRISBANE, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, today announced that its lead drug candidate, BSI-201, which is in Phase 2 clinical trials for multiple cancer indications, has been selected as one of the Top 10 Most Interesting Oncology Projects Available for Partnering. An independent committee assembled by Windhover Information made the selection. Windhover is a leading...

2008-04-10 09:01:02

BRISBANE, Calif., April 10 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme (GBM), the most common glioma in adults. BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in BiPar's DNA repair portfolio, crosses the blood-brain barrier, a unique property that enables its targeted investigation in the brain tumor setting. This study is being conducted by...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related